Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (55 quarters reported)
$233M in Q4 2012 → $1.85M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| SE Space Exploration Techn Corp | 24.0% | New | 2,606 | $445K |
| BH Berkshire Hathaway Inc Del | 20.3% | Added 3.7% | 754 | $377K |
| Alphabet Inc | 13.3% | New | 691 | $247K |
| VI Vanguard Index Fds | 12.6% | New | 339 | $233K |
| Blackstone Inc | 10.2% | New | 1,597 | $188K |
| Kyverna Therapeutics Inc | 5.9% | Trimmed 34% | 12,347 | $110K |
| Lexeo Therapeutics Inc | 4.3% | Added 22% | 16,962 | $79K |
| X4 Pharmaceuticals Inc | 3.9% | Unchanged | 15,557 | $72.7K |
| Inhibikase Therapeutics Inc | 3.1% | Unchanged | 28,453 | $57.8K |
| AO Alx Oncology Hldgs Inc | 2.3% | Unchanged | 20,946 | $43.4K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SG SPDR Gold Tr | Exited | −7,623 | −$3.28M | — |
| SE Space Exploration Techn Corp | New | +2,606 | +$445K | 24.0% |
| Alphabet Inc | New | +691 | +$247K | 13.3% |
| VI Vanguard Index Fds | New | +339 | +$233K | 12.6% |
| Blackstone Inc | New | +1,597 | +$188K | 10.2% |
| Kyverna Therapeutics Inc | Trimmed | −6,426 | −$57.3K | 5.9% |
| Lexeo Therapeutics Inc | Added | +3,019 | +$14.1K | 4.3% |
| BH Berkshire Hathaway Inc Del | Added | +27 | +$13.5K | 20.3% |
quarter ended March 31, 2026 · filed May 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Spyre Therapeutics Inc | Exited | −8,919 | −$292K | — |
| SG SPDR Gold Tr | Added | +659 | +$284K | 81.5% |
| MM Mind Medicine Mindmed Inc | Exited | −15,688 | −$210K | — |
| Compass Therapeutics Inc | Exited | −29,495 | −$158K | — |
| AO Alx Oncology Hldgs Inc | New | +20,946 | +$42K | 1.0% |
| Sab Biotherapeutics Inc | Exited | −10,527 | −$39.4K | — |
| Context Therapeutics Inc | Exited | −18,403 | −$27.1K | — |
| BH Berkshire Hathaway Inc Del | Added | +17 | +$8.15K | 8.7% |
quarter ended December 31, 2025 · filed February 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Rezolute Inc | Exited | −1,986,818 | −$18.7M | — |
| Spyre Therapeutics Inc | New | +8,919 | +$292K | 6.8% |
| Enliven Therapeutics Inc | Exited | −13,097 | −$268K | — |
| Bicara Therapeutics Inc | Exited | −10,941 | −$173K | — |
| MM Mind Medicine Mindmed Inc | Trimmed | −11,323 | −$152K | 4.9% |
| Compass Therapeutics Inc | Trimmed | −24,008 | −$129K | 3.7% |
| SG SPDR Gold Tr | Trimmed | −322 | −$128K | 64.5% |
| X4 Pharmaceuticals Inc | New | +15,557 | +$62.2K | 1.5% |
| Kyverna Therapeutics Inc | Trimmed | −4,208 | −$39.6K | 4.1% |
| Lexeo Therapeutics Inc | Trimmed | −3,389 | −$33.7K | 3.2% |
Showing the 10 largest of 13 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Rezolute Inc | Added | +382,832 | +$3.6M | 81.7% |
| SG SPDR Gold Tr | Added | +2,334 | +$830K | 11.3% |
| MM Mind Medicine Mindmed Inc | Trimmed | −7,062 | −$83.3K | 1.4% |
| Compass Therapeutics Inc | Added | +10,038 | +$35.1K | 0.8% |
| Sab Biotherapeutics Inc | New | +10,935 | +$22K | 0.1% |
| BH Berkshire Hathaway Inc Del | Added | +19 | +$9.56K | 1.4% |
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Rezolute Inc | Added | +285,019 | +$1.27M | 72.6% |
| SG SPDR Gold Tr | Added | +3,654 | +$1.11M | 15.3% |
| Enliven Therapeutics Inc | New | +13,097 | +$263K | 2.7% |
| BH Berkshire Hathaway Inc Del | Added | +165 | +$80.2K | 3.1% |
| Cardiff Oncology Inc | Exited | −13,287 | −$41.7K | — |
| Adicet Bio Inc | Exited | −17,488 | −$13.2K | — |
| Lexeo Therapeutics Inc | Trimmed | −519 | −$2.09K | 0.7% |
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Xeris Biopharma Holdings Inc | Exited | −2,015,157 | −$6.83M | — |
| SS SPDR S&P 500 ETF Tr | Exited | −2,823 | −$1.65M | — |
| BH Berkshire Hathaway Inc Del | Trimmed | −666 | −$355K | 4.9% |
| G Glycomimetics Inc | Exited | −203,578 | −$50.9K | — |
| SG SPDR Gold Tr | Added | +129 | +$37.2K | 7.4% |
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Xeris Biopharma Holdings Inc | Trimmed | −3,098,191 | −$10.5M | 41.1% |
| SG SPDR Gold Tr | New | +1,169 | +$283K | 1.7% |
| Abivax Sa | Exited | −11,365 | −$131K | — |
| Cardiff Oncology Inc | New | +13,287 | +$57.7K | 0.3% |
| Inhibikase Therapeutics Inc | New | +16,393 | +$53.3K | 0.3% |
| G Glycomimetics Inc | New | +203,578 | +$50.9K | 0.3% |
| SS SPDR S&P 500 ETF Tr | Trimmed | −44 | −$25.8K | 9.9% |
| BH Berkshire Hathaway Inc Del | Trimmed | −18 | −$8.16K | 3.1% |
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS SPDR S&P 500 ETF Tr | Added | +998 | +$573K | 6.8% |
| Bicara Therapeutics Inc | New | +10,941 | +$279K | 1.2% |
| MT Molecular Templates Inc | Exited | −136,866 | −$157K | — |
| BH Berkshire Hathaway Inc Del | Added | +126 | +$58K | 2.2% |
| Abivax Sa | Trimmed | −2,535 | −$29.2K | 0.5% |
| MM Mind Medicine Mindmed Inc | Added | +3,690 | +$21K | 0.8% |
Loading...
